276 related articles for article (PubMed ID: 34838715)
1. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
2. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
3. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
4. Liver X Receptor Alpha Activation Inhibits Autophagy and Lipophagy in Hepatocytes by Dysregulating Autophagy-Related 4B Cysteine Peptidase and Rab-8B, Reducing Mitochondrial Fuel Oxidation.
Kim YS; Nam HJ; Han CY; Joo MS; Jang K; Jun DW; Kim SG
Hepatology; 2021 Apr; 73(4):1307-1326. PubMed ID: 32557804
[TBL] [Abstract][Full Text] [Related]
5. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
7. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
[TBL] [Abstract][Full Text] [Related]
8. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
9. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Crtc2 controls whole body energy metabolism via a miR-34a-Fgf21 axis.
Han HS; Choi BH; Kim JS; Kang G; Koo SH
Nat Commun; 2017 Nov; 8(1):1878. PubMed ID: 29192248
[TBL] [Abstract][Full Text] [Related]
11. Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a.
Wang Z; Zhu Y; Xia L; Li J; Song M; Yang C
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615779
[TBL] [Abstract][Full Text] [Related]
12. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
13. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
14. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
15. Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy.
Stacchiotti A; Grossi I; García-Gómez R; Patel GA; Salvi A; Lavazza A; De Petro G; Monsalve M; Rezzani R
Cells; 2019 Sep; 8(9):. PubMed ID: 31500354
[TBL] [Abstract][Full Text] [Related]
16. The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation.
Kim H
Sci Rep; 2016 Nov; 6():37280. PubMed ID: 27869139
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis.
BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS
Arch Physiol Biochem; 2024 Jun; 130(3):300-315. PubMed ID: 35254877
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
Zhang M; Sun W; Zhou M; Tang Y
Sci Rep; 2017 Nov; 7(1):14493. PubMed ID: 29101357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
